Treace Announces Participation in the Bank of America 2023 Healthcare Conference

Rhea-AI Summary

Treace Medical Concepts, Inc. (TMCI), a medical technology firm specializing in bunion treatment, announced that CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat at the Bank of America 2023 Healthcare Conference on May 10, 2023, at 11:40 AM ET. The event will focus on Treace's innovative Lapiplasty® 3D Bunion Correction™ Procedure, aimed at improving surgical outcomes for bunion patients. The company estimates around 1.1 million Americans are annual surgical candidates for bunion correction. A live webcast of the session will be available on Treace's investor relations website.

Positive

• Participation in a significant healthcare conference may enhance visibility.
• Lapiplasty® 3D Bunion Correction™ could attract investor and market interest.
• Estimated 1.1 million annual surgical candidates presents a large potential market.

Negative

• None.

PONTE VEDRA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Bank of America 2023 Healthcare Conference on Wednesday, May 10, 2023, beginning at approximately 11:40 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:

Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:

Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com

FAQ

When will Treace Medical Concepts participate in the Bank of America Healthcare Conference?

Treace Medical Concepts will participate in the Bank of America 2023 Healthcare Conference on May 10, 2023.

Who will represent Treace Medical Concepts at the conference?

CEO John T. Treace and CFO Mark L. Hair will represent Treace Medical Concepts.

What is the significance of the Lapiplasty® 3D Bunion Correction™ Procedure?

The Lapiplasty® 3D Bunion Correction™ Procedure aims to improve surgical treatment outcomes for bunions.

Where can I watch the fireside chat from the conference?

You can watch the fireside chat live on Treace Medical Concepts' investor relations website.

What is the market potential for Treace Medical Concepts' bunion treatments?

Treace estimates about 1.1 million Americans are annual surgical candidates for bunion correction.